NASDAQ:ILMN - Illumina Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $307.09 +6.50 (+2.16 %) (As of 05/21/2019 03:24 PM ET)Previous Close$300.59Today's Range$302.40 - $313.0852-Week Range$261.61 - $372.61Volume36,391 shsAverage Volume981,761 shsMarket Capitalization$45.14 billionP/E Ratio53.67Dividend YieldN/ABeta1.15 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. has a partnership with Lundbeck Foundation GeoGenetics Centre for exploring the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens; and an agreement with HTG Molecular Diagnostics, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California. Receive ILMN News and Ratings via Email Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:ILMN Previous Symbol CUSIP45232710 CIK1110803 Webwww.illumina.com Phone858-202-4500Debt Debt-to-Equity Ratio0.27 Current Ratio3.66 Quick Ratio3.33Price-To-Earnings Trailing P/E Ratio53.67 Forward P/E Ratio45.97 P/E Growth2.14 Sales & Book Value Annual Sales$3.33 billion Price / Sales13.54 Cash Flow$7.2650 per share Price / Cash Flow42.27 Book Value$27.69 per share Price / Book11.09Profitability EPS (Most Recent Fiscal Year)$5.72 Net Income$826 million Net Margins25.06% Return on Equity23.49% Return on Assets12.95%Miscellaneous Employees7,300 Outstanding Shares147,000,000Market Cap$45.14 billion Next Earnings Date7/29/2019 (Estimated) OptionableOptionable Illumina (NASDAQ:ILMN) Frequently Asked Questions What is Illumina's stock symbol? Illumina trades on the NASDAQ under the ticker symbol "ILMN." How were Illumina's earnings last quarter? Illumina, Inc. (NASDAQ:ILMN) issued its quarterly earnings results on Thursday, April, 25th. The life sciences company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.34 by $0.26. The life sciences company earned $846 million during the quarter, compared to analysts' expectations of $838.70 million. Illumina had a return on equity of 23.49% and a net margin of 25.06%. The business's quarterly revenue was up 8.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.45 earnings per share. View Illumina's Earnings History. When is Illumina's next earnings date? Illumina is scheduled to release their next quarterly earnings announcement on Monday, July 29th 2019. View Earnings Estimates for Illumina. What guidance has Illumina issued on next quarter's earnings? Illumina issued an update on its FY19 earnings guidance on Thursday, April, 25th. The company provided earnings per share (EPS) guidance of $6.63-6.73 for the period, compared to the Thomson Reuters consensus estimate of $6.53. The company issued revenue guidance of $3.766-3.799 billion, compared to the consensus revenue estimate of $3.78 billion.Illumina also updated its FY 2019 guidance to $6.63-6.73 EPS. What price target have analysts set for ILMN? 13 brokerages have issued 12 month price targets for Illumina's stock. Their forecasts range from $288.00 to $400.00. On average, they expect Illumina's stock price to reach $353.4608 in the next year. This suggests a possible upside of 14.9% from the stock's current price. View Analyst Price Targets for Illumina. What is the consensus analysts' recommendation for Illumina? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Illumina. What are Wall Street analysts saying about Illumina stock? Here are some recent quotes from research analysts about Illumina stock: 1. Canaccord Genuity analysts commented, "We view Q1 as mixed, but we reiterate our BUY rating since less than 0.02% of humans have ever been sequenced and clinical sequencing is growing rapidly off an extremely low base. We narrowly trim our revenue estimates and lower our PT to $350." (4/26/2019) 2. According to Zacks Investment Research, "Illumina continues to register strong top line growth across the company’s high throughput, mid throughput and low throughput categories. In the last-reported fourth quarter, the company observed strong demand for sequencing and array systems, consumables and services. Meanwhile HiSeq to NovaSeq upgrade cycle is progressing well and NextSeq placements are strong. We are also looking forward to the company's newly-inked Pacific Biosciences deal. In the past year, Illumina has outperformed its industry. However, we note that, Illumina exited the fourth quarter of 2018 on a mixed note with earnings lagging the Zacks Consensus Estimate. HiSeq consumables are continuing with their expected decline. Seasonality in DTC functionality continues to dent Illumina’s microarray sales. Funding issues restrict growth. The company is operating in a tough competitive landscape." (4/2/2019) Has Illumina been receiving favorable news coverage? News articles about ILMN stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Illumina earned a daily sentiment score of 1.3 on InfoTrie's scale. They also gave headlines about the life sciences company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. Who are some of Illumina's key competitors? Some companies that are related to Illumina include Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), PerkinElmer (PKI), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Fluidigm (FLDM), Quanterix (QTRX), Eyepoint Pharmaceuticals (EYPT) and Harvard Bioscience (HBIO). What other stocks do shareholders of Illumina own? Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Celgene (CELG), Gilead Sciences (GILD), Adobe (ADBE), Baidu (BIDU), Visa (v), Micron Technology (MU) and Tesla (TSLA). Who are Illumina's key executives? Illumina's management team includes the folowing people: Mr. Jay T. Flatley, Exec. Chairman (Age 66)Mr. Francis A. deSouza, CEO, Pres & Director (Age 48)Mr. Sam A. Samad, CFO & Sr. VP (Age 49)Mr. Omead Ostadan, Sr. VP of Products, Marketing & Strategic Planning (Age 47)Ms. Aimee L. Hoyt, Chief People Officer & Sr. VP (Age 48) Who are Illumina's major shareholders? Illumina's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (10.87%), Jennison Associates LLC (3.86%), Northern Trust Corp (1.13%), Viking Global Investors LP (0.80%), Jackson Square Partners LLC (0.77%) and Primecap Management Co. CA (0.68%). Company insiders that own Illumina stock include A Blaine Bowman, Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Michel Bouchard, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan and Robert S Epstein. View Institutional Ownership Trends for Illumina. Which major investors are selling Illumina stock? ILMN stock was sold by a variety of institutional investors in the last quarter, including Lazard Asset Management LLC, CNH Partners LLC, Lombard Odier Asset Management USA Corp, Macquarie Group Ltd., Jackson Square Partners LLC, Eagle Asset Management Inc., AQR Capital Management LLC and Carillon Tower Advisers Inc.. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan and Robert S Epstein. View Insider Buying and Selling for Illumina. Which major investors are buying Illumina stock? ILMN stock was purchased by a variety of institutional investors in the last quarter, including American Century Companies Inc., MERIAN GLOBAL INVESTORS UK Ltd, Jennison Associates LLC, Renaissance Technologies LLC, ARK Investment Management LLC, Principal Financial Group Inc., Sumitomo Mitsui Trust Holdings Inc. and Nikko Asset Management Americas Inc.. View Insider Buying and Selling for Illumina. How do I buy shares of Illumina? Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Illumina's stock price today? One share of ILMN stock can currently be purchased for approximately $307.64. How big of a company is Illumina? Illumina has a market capitalization of $45.22 billion and generates $3.33 billion in revenue each year. The life sciences company earns $826 million in net income (profit) each year or $5.72 on an earnings per share basis. Illumina employs 7,300 workers across the globe. What is Illumina's official website? The official website for Illumina is http://www.illumina.com. How can I contact Illumina? Illumina's mailing address is 5200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected] MarketBeat Community Rating for Illumina (NASDAQ ILMN)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 916 (Vote Outperform)Underperform Votes: 816 (Vote Underperform)Total Votes: 1,732MarketBeat's community ratings are surveys of what our community members think about Illumina and other stocks. Vote "Outperform" if you believe ILMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ILMN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: What is a Lock-Up Period? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.